1083181-70-7 Usage
Uses
Used in Pharmaceutical Industry:
2-(1-Benzylpiperidin-3-yl)ethanamine is used as a therapeutic agent for the treatment of chronic pain due to its potent agonist activity at the δ-opioid receptor, offering effective pain relief without the severe side effects associated with traditional opioids.
Used in Mental Health Applications:
In the field of mental health, 2-(1-Benzylpiperidin-3-yl)ethanamine is utilized as a mood stabilizer and antidepressant, leveraging its anxiolytic and antidepressant properties to alleviate symptoms of mood disorders.
Used in Pain Management:
2-(1-Benzylpiperidin-3-yl)ethanamine is employed as an analgesic agent, providing pain relief through its interaction with the δ-opioid receptor, making it a valuable asset in the management of both acute and chronic pain conditions.
Used in Drug Development Research:
In the realm of drug development, 2-(1-Benzylpiperidin-3-yl)ethanamine serves as a key compound in research aimed at understanding the δ-opioid receptor's role in pain and mood regulation, potentially leading to the discovery of new medications with improved safety profiles.
Check Digit Verification of cas no
The CAS Registry Mumber 1083181-70-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,8,3,1,8 and 1 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1083181-70:
(9*1)+(8*0)+(7*8)+(6*3)+(5*1)+(4*8)+(3*1)+(2*7)+(1*0)=137
137 % 10 = 7
So 1083181-70-7 is a valid CAS Registry Number.
1083181-70-7Relevant academic research and scientific papers
Structure-activity relationship study of tryptophan-based butyrylcholinesterase inhibitors
Brazzolotto, Xavier,Gobec, Stanislav,Gro?elj, Uro?,Knez, Damijan,Malikowska-Racia, Natalia,Meden, An?e,Nachon, Florian,Sa?at, Kinga,Svete, Jurij
, (2020/09/15)
A series of tryptophan-based selective nanomolar butyrylcholinesterase (BChE) inhibitors was designed and synthesized. Compounds were optimized in terms of potency, selectivity, and synthetic accessibility. The crystal structure of the inhibitor 18 in complex with BChE revealed the molecular basis for its low nanomolar inhibition (IC50 = 2.8 nM). The favourable in vitro results enabled a first-in-animal in vivo efficacy and safety trial, which demonstrated a positive impact on fear-motivated and spatial long-term memory retrieval without any concomitant adverse motor effects. Altogether, this research culminated in a handful of new lead compounds with promising potential for symptomatic treatment of patients with Alzheimer's disease.
